| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 |
|---|---|---|---|---|
Gross Sales | 9,199.93 | 7,893.67 | 6,696.77 | 6,055.79 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 9,199.93 | 7,893.67 | 6,696.77 | 6,055.79 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 297.27 | 201.53 | 90.71 | 171.87 |
Total Income | 9,497.2 | 8,095.2 | 6,787.48 | 6,227.67 |
Total Expenditure | 6,838.33 | 5,949.71 | 5,212.81 | 4,351.27 |
PBIDT | 2,658.87 | 2,145.49 | 1,574.67 | 1,876.39 |
Interest | 238.94 | 24.15 | 39.31 | 45.58 |
PBDT | 2,419.93 | 2,121.34 | 1,535.35 | 1,830.81 |
Depreciation | 405.66 | 293.56 | 241.4 | 119.26 |
Minority Interest Before NP | 0 | 0 | 0 | 0 |
Tax | 464.59 | 378.06 | 238.44 | 454.68 |
Deferred Tax | -36.79 | -15.46 | 39.54 | -3.37 |
Reported Profit After Tax | 1,586.47 | 1,465.18 | 1,015.98 | 1,260.24 |
Minority Interest After NP | 16.28 | 23.52 | 19.56 | 16.85 |
Net Profit after Minority Interest | 1,570.19 | 1,441.66 | 996.42 | 1,243.4 |
Extra-ordinary Items | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 1,570.19 | 1,441.66 | 996.42 | 1,243.4 |
EPS (Unit Curr.) | 39.14 | 35.99 | 24.87 | 31.04 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 |
Equity | 40.06 | 40.06 | 40.06 | 40.06 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 |
PBIDTM(%) | 28.9 | 27.17 | 23.51 | 30.98 |
PBDTM(%) | 26.3 | 26.87 | 22.92 | 30.23 |
PATM(%) | 17.24 | 18.56 | 15.17 | 20.81 |
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.
The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.
According to the National Cancer Registry Programme, cancer is expected to cause 29.8 million DALYs by 2025, making it a serious health issue in India.
The issue price includes a premium of ₹2,519 per share, aggregating a total of ₹2,999.99 crore.
Revenue from operations grew by 13.6% YoY, totaling ₹3,076.5 Crore, up from ₹2,708.1 Crore in Q2 of the previous fiscal.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s, Hindustan Zinc, Titan Company, etc.
Here are some of the stocks that may see significant price movement today: Escorts Kubota, Infosys, Mahindra & Mahindra, etc.
Mankind announced in July that it would purchase the whole stake in Bharat Serums and Vaccines.
Here are some of the stocks that may see significant price movement today: Suzlon Energy, Aurobindo Pharma, Coal India, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
